• A brown building with white vertical sign with the Twitter logo
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images

    With Twitter in flux, pharma is turning to alternative social spaces

    Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging.

    By Jan. 26, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    By Jan. 26, 2023
  • Lauren Lazar Calcium
    Image attribution tooltip
    Permission granted by Lauren Lazar Calcium

    Woman of the Week: Dr. Lauren Lazar

    As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

    By Jan. 25, 2023
  • J&J CEO Joaquin Duato
    Image attribution tooltip
    Mike Coppola via Getty Images

    Economic crisis? J&J execs say that won’t stop them from hitting $60B target

    The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times.

    By Jan. 25, 2023
  • High angle shot of a group of medical practitioners analyzing x-rays on a digital tablet in a hospital.
    Image attribution tooltip
    Stock via Getty Images

    Report reveals murky picture of clinical trial diversity gains

    Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

    By Alexandra Pecci • Jan. 24, 2023
  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    magicmine, iStock / Getty Images Plus via Getty Images

    AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships

    A longtime leader in the respiratory space, AstraZeneca has hammered another stake in the ground with its newest asthma treatment, Airsupra.

    By Jan. 24, 2023
  • A prescription bottle with white pills and a wooden gavel sit atop a $100 bill showing Benjamin Franklin's face.
    Image attribution tooltip
    Bill Oxford via Getty Images

    Drug price negotiations: 5 key dates to watch

    As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.

    By Kelly Bilodeau • Jan. 23, 2023
  • Astellas' U.S. headquarters in Northbrook, IL.
    Image attribution tooltip
    Permission granted by Astellas

    Already on a roll in oncology, Astellas hunts for big wins in other areas

    With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

    By Jan. 23, 2023
  • Bekki Brown UBC
    Image attribution tooltip
    Permission granted by Bekki Brown
    Q&A // First 90 Days

    UBC crowns Bekki Brown as its new CEO with a clear mandate to grow

    The first-time CEO is tapping into decades of operational expertise to help bring real-world data into the mainstream.

    By Jan. 20, 2023
  • The headquarters of the FDA, which has recently issued a recall for Teleflex air filters used in hospital respirators.
    Image attribution tooltip
    Sarah Silbiger/Getty Images via Getty Images

    FDA’s 2022 drug approvals fall short of recent norms

    The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.

    By Alexandra Pecci • Jan. 19, 2023
  • Novavax vaccine
    Image attribution tooltip
    Carsten Koall via Getty Images

    After ‘limping along,’ Novavax sees a path forward

    With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.

    By Jan. 18, 2023
  • Sean McCarthy, CEO and chairman, CytomX
    Image attribution tooltip
    Permission granted by CytomX

    A Moderna tie-up ushers in new era for CytomX

    The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

    By Jan. 18, 2023
  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    JuSun via Getty Images

    The M&A hunt is on — here are the prime targets

    Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.

    By Kelly Bilodeau • Jan. 17, 2023
  • Viewed from above, a rendering of the COVID-19 virus sits in the center of a clay, red basketball court.
    Image attribution tooltip
    Enes Evren via Getty Images

    Pro sports’ COVID protocols led to real-world data impacts for pharma

    After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

    By Jan. 16, 2023
  • financial storm
    Image attribution tooltip
    Stock via Getty Images

    How biotechs can weather the market storm

    Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

    By Jan. 13, 2023
  • International Space Station
    Image attribution tooltip
    iStock via Getty Images

    Space — the next frontier in drug development

    Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

    By Kelly Bilodeau • Jan. 12, 2023
  • M&A handshake
    Image attribution tooltip
    iStock via Getty Images

    Biopharma M&A may get the push it needs in 2023, but with a face lift

    A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

    By Jan. 12, 2023
  • Claire Aldridge Form Bio
    Image attribution tooltip
    Permission granted by Claire Aldridge Form Bio

    Woman of the Week: Form Bio’s Claire Aldridge

    The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

    By Jan. 11, 2023
  • A photograph of a Biogen building located in Cambridge, Massachusetts, on Oct. 22, 2015.
    Image attribution tooltip

    Nicolaus Czarnecki/Zuma Press/Newscom

    Making Moves

    C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans

    A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.

    By Jan. 10, 2023
  • Karate
    Image attribution tooltip
    grapix via Getty Images

    The kindred nature of martial arts and drug development

    How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

    By Alexandra Pecci • Jan. 9, 2023
  • An aerial view of San Francisco
    Image attribution tooltip
    Stock via Getty Images

    What’s top of mind for industry execs at JPM?

    Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

    By Jan. 6, 2023
  • pink hourglass
    Image attribution tooltip
    Stock via Getty Images

    A new mission in menopause — extending the lives of women

    Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.

    By Jan. 5, 2023
  • Alzheimer's road
    Image attribution tooltip
    Cemile Bingol via Getty Images

    Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

    As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

    By Jan. 5, 2023
  • spilled vial
    Image attribution tooltip
    Stock via Getty Images

    Nonprofits are bridging R&D’s valley of death

    How charitable firms such as Advancium are helping to right the market wrongs of drug development.

    By Kelly Bilodeau • Jan. 4, 2023
  • Norman Sussman, chief medical officer, Durect
    Image attribution tooltip
    Permission granted by Durect

    Forks in the road lead one medical expert to a ‘game changing’ liver treatment

    Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

    By Alexandra Pecci • Jan. 3, 2023